Pemigatinib

Drug Overview

Pemigatinib is a small molecule, orally available, selective inhibitor of the fibroblast growth factor receptor (FGFR) family. It represents a highly targeted therapy used primarily to treat certain cancers driven by FGFR gene fusions or rearrangements.

• Generic Name: Pemigatinib
• US Brand Names: Pemazyre®
• Drug Class: Fibroblast Growth Factor Receptor (FGFR) Inhibitor, Kinase Inhibitor
• Route of Administration: Oral (Tablet)
• FDA Approval Status: Approved for oncological indications
  
  Pemigatinib is the best targeted therapy for bile duct cancer. Read about the powerful benefits of this life-saving oncology medication.

What Is It and How Does It Work? (Mechanism of Action)

Pemigatinib is a targeted tyrosine kinase inhibitor that specifically blocks the FGFR pathway, which is often aberrantly activated in various cancers. This drug is only effective in cancers that show these genetic alterations.

• Molecular Target: The drug potently and selectively inhibits the kinase activity of Fibroblast Growth Factor Receptor (FGFR) isoforms 1, 2, and 3.
• Cellular Impact: In many cancers, particularly intrahepatic cholangiocarcinoma (iCCA), genetic alterations like FGFR2 fusions or rearrangements lead to the continuous, ligand-independent activation of the FGFR signaling pathway. This aberrant signaling drives cell proliferation and survival. Pemigatinib works by binding to the active site of the FGFR kinase, thereby blocking the autophosphorylation and subsequent downstream signaling.
• Result (Anti-Proliferation/Apoptosis): By inhibiting the constitutively activated FGFR signaling pathway, pemiaatinib suppresses tumor cell growth and ultimately induces apoptosis (programmed cell death) in cells dependent on the FGFR pathway.
• Bone Affinity: The drug has also shown preclinical activity against other FGFR-driven malignancies, including some with bone involvement like bladder cancer and myeloproliferative neoplasms.

FDA-Approved Clinical Indications

Pemigatinib is FDA-approved for specific cancer types, requiring mandatory prior genetic testing.

Oncological Uses

• Cholangiocarcinoma (CCA): Indicated for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with a Fibroblast Growth Factor Receptor 2 (FGFR2) fusion or rearrangement. This was approved under accelerated approval.
• Myeloid/Lymphoid Neoplasms (MLNs): Indicated for adults with relapsed or refractory MLNs with {FGFR1} rearrangement. This was approved under accelerated approval.

Non-oncological Uses

• No current FDA-approved non-oncological indications were found.

Dosage and Administration Protocols

Pemigatinib is administered orally on a continuous cycle with mandatory breaks to manage toxicity.

Dose Adjustments and Special Considerations

Clinical Efficacy and Research Results (2020-2025 Context)

Pemigatinib demonstrated significant clinical activity in the FIGHT-202 trial, leading to its accelerated approval.

• Objective Response Rate (ORR): In previously treated CCA patients with{FGFR2} fusions/rearrangements, the ORR was 35.5%. This rate was significantly higher than the typical response to second-line chemotherapy.
• Duration of Response (DOR): The median duration of response was 7.5 months.
• Complete Response (CR): Among the responders in the CCA cohort, 2.8% achieved a complete response.
• Myeloid/Lymphoid Neoplasms (MLNs): In the trial for MLNs with {FGFR1} rearrangement, the complete response rate (CR) was 78% in the cohort that was eligible for evaluation. This durable response rate led to the accelerated approval.

Safety Profile and Side Effects

Critical Warning: Ocular Toxicity

Pemigatinib can cause serious eye problems, including retinal pigment epithelial (RPE) detachment (seen in 4%-6% of patients) and central serous retinopathy. Ocular examination is mandatory before starting treatment, every 2 months for the first 6 months, and every 3 months thereafter.

Common Side Effects (>10%)

• Metabolic: Hyperphosphatemia (high phosphate levels) (60%), hypophosphatemia, hypokalemia.
• Systemic: Alopecia (42%), fatigue (42%), dysgeusia (altered sense of taste) (40%).
• Gastrointestinal: Diarrhea (37%), nausea (36%), constipation (36%), stomatitis (30%).
• Dermatologic: Nail toxicity (29%), palmar-plantar erythrodysesthesia syndrome (PPE) (19%), dry skin.

Serious Adverse Events

4. Hyperphosphatemia: This is an expected, mechanism-based side effect. Uncontrolled hyperphosphatemia can lead to calcification of soft tissues (e.g., eyes, skin). Management requires dose modification or dietary phosphate restriction.
5. Ocular Toxicity: Retinal Pigment Epithelial (RPE) detachment can cause blurred vision, flashes of light, and floaters.
6. Embryo-Fetal Toxicity: The drug can cause fetal harm when administered to a pregnant woman.
7. Fibroblast Growth Factor (FGF) Syndrome: A rare but potentially serious complication that can include calcification and vascular issues.

Connection to Stem Cell & Regenerative Medicine

Pemigatinib’s mechanism, while focused on oncology, is inherently tied to the biology of cell growth and differentiation pathways:

• FGFR Pathway and Development: The FGFR signaling pathway is a key regulator of normal cellular processes, including embryonic development, tissue repair, and the differentiation of stem and progenitor cells. By blocking this pathway, pemigatinib interferes with these biological functions.
• Targeting Progenitor Cells: FGFRs play a role in the survival and proliferation of hematopoietic stem and progenitor cells, which is why {FGFR1} rearrangement is an oncogenic driver in MLNs. The successful use of pemigatinib in MLNs demonstrates its ability to halt the uncontrolled proliferation of these transformed progenitor cells.
• Research in Tissue Repair: The toxicity profile, including nail and hair changes and RPE detachment, is a direct consequence of inhibiting FGFR in rapidly dividing/regenerating tissues, highlighting the drug’s potent anti-regenerative effect in non-cancerous cells.

Patient Management and Practical Recommendations

Pre-treatment

• Genetic Testing: Patient selection must be based on a confirmed {FGFR2} fusion/rearrangement for CCA or {FGFR1} rearrangement for MLN, using a validated test.
• Ophthalmological Exam: A comprehensive ophthalmological examination must be conducted before starting therapy.
• Labs: Obtain baseline phosphate and calcium levels.

Precautions During Treatment

• Ocular Monitoring: Follow the strict ophthalmological exam schedule (before treatment, at 2, 4, and 6 months, and every 3 months thereafter) to monitor for RPE detachment.
• Phosphate Management: Monitor serum phosphate levels weekly for the first month, and then monthly. Manage hyperphosphatemia with dietary restriction and/or phosphate-lowering therapy.
• Contraception: Female patients must use effective contraception during treatment and for 1 month after the last dose. Male patients with partners who can become pregnant must use effective contraception during treatment and for 1 month after the last dose.

Do’s and Don’ts

• DO:
  • DO: Contact your eye care specialist immediately if you experience new or worsening symptoms like blurred vision, dark spots, flashing lights, or floaters.
  • DO: Keep your phosphate levels within the normal range as directed by your physician (e.g., via low-phosphate diet or medication).
  • DO: Avoid grapefruit or grapefruit juice, as these can increase drug concentrations.
• DON’T:
  • DON’T: Skip the mandatory ophthalmology exams; they are critical for preventing permanent vision loss.
  • DON’T: Stop, hold, or reduce the dose of pemigatinib without consulting your oncologist.
  • DON’T: Breastfeed during treatment and for 1 month after the last dose.

Legal Disclaimer

This guide is for informational purposes only and is intended for international patients and healthcare professionals. It does not replace professional medical advice, diagnosis, or treatment. Dosing and protocols may vary by patient status, concurrent therapies, and local regulatory guidelines. Always consult with a qualified oncologist or healthcare provider regarding specific medical conditions and treatment plans.